Perindopril decreases P wave dispersion in patients with stage 1 hypertension

Abstract

Introduction. Angiotensin-converting enzyme inhibitors prevent atrial fibrillation episodes by effective control of blood pressure and improving electrical and structural remodelling in the atria. Increased P wave dispersion (PWD) is a non-invasive electrocardiographic marker for paroxysmal atrial fibrillation. The aim of the study was to evaluate the effect of perindopril treatment on PWD in hypertensive patients. Methods. Forty-eight hypertensive patients (mean age 57.4±11.8 years, 18 men) were included. Blood pressure values were determined and 12-lead electrocardiograms were recorded at the beginning and at the first week, first month, third month and sixth month of the perindopril treatment.The difference between maximum and minimum P wave durations was calculated as PWD.

Results. PWDs were significantly shortened at the first, third and sixth months (41.7±8.8 ms, 39.1±6.9 ms and 38.3±7.1 ms, respectively) compared with baseline and first-week measurements (54.3±9.2 ms and 49.0±9.1 ms, respectively, p<0.001). Baseline PWD was correlated with body mass index (r=0.32, p=0.026), while PWD at the sixth month of treatment was significantly correlated with left atrial volume index (r=0.30, p=0.042). Multiple linear regression analysis revealed that PWD at the sixth month was related to baseline PWD (p=0.001).

Conclusion. Perindopril treatment significantly reduced PWD in hypertensive patients.

Keywords

angiotensin-converting enzyme inhibitor atrial fibrillation electrocardiography hypertension perindopril P wave dispersion

Get full access to this article

View all access options for this article.

References

Go AS , Hylek EM , Phillips KA et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-5.

Stewart S. , Hart CL , Hole DJ , McMurray JJ A population-based study of the long-term risks associated with atrial fibrillation: 20-year follow-up of the Renfrew/Paisley study. Am J Med 2002; 113:359-64.

Vidaillet H. , Granada JF , Chyou PH et al. A population-based study of mortality among patients with atrial fibrillation or flutter. Am J Med 2002; 113:365-70.

Krahn AD , Manfreda J. , Tate RB , Mathewson FA , Cuddy TE The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med 1995;98:476-84.

Kannel WB , Wolf PA , Benjamin EJ , Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998 ; 82:2N-9N.

Healey JS , Connolly SJ Atrial fibrillation: hypertension as a causative agent, risk factor for complications, and potential therapeutic target. Am J Cardiol 2003;91:9G-14G.

Verdecchia P. , Reboldi G. , Gattobigio R. et al. Atrial fibrillation in hypertension: predictors and outcome. Hypertension 2003;41:218-23.

Geller JC Atrial fibrillation as end point of hypertension. Can antihypertensive therapy prevent it? MMW Fortschr Med 2003;145:38-41.

Dilaveris PE , Gialafos EJ , Sideris SK et al. Simple electrocardiographic markers for the prediction of paroxysmal idiopathic atrial fibrillation. Am Heart J 1998;135:733-8.

10.

Dilaveris PE , Gialafos EJ , Andrikopoulos GK et al. Clinical and electrocardiographic predictors of recurrent atrial fibrillation. Pacing Clin Electrophysiol 2000;23:352-8.

11.

Babaev AA , Vloka ME , Sadurski R. , Steinberg JS Influence of age on atrial activation as measured by the P-wave signal-averaged electrocardiogram. Am J Cardiol 2000;86:692-5.

12.

Michelucci A. , Bagliani G. , Colella A. et al. P wave assessment: state of the art update. Card Electrophysiol Rev 2002; 6:215-20.

13.

Celik T. , Iyisoy A. , Kursaklioglu H. et al. The comparative effects of telmisartan and ramipril on P-wave dispersion in hypertensive patients: a randomized clinical study. Clin Cardiol 2005;28:298-302.

14.

Benjamin EJ , Levy D. , Vaziri SM , D'Agostino RB , Belanger AJ , Wolf PA Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA 1994;271:840-4.

15.

Allessie MA

Atrial electrophysiologic remodeling: another vicious circle?

J Cardiovasc Electrophysiol 1998;9:1378-93.

16.

Nattel S. , Shiroshita-Takeshita A. , Cardin S. , Pelletier P. Mechanisms of atrial remodeling and clinical relevance. Curr Opin Cardiol 2005;20:21-5.

17.

Nakashima H. , Kumagai K. , Urata H. , Gondo N. , Ideishi M. , Arakawa K. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000;101:2612-17.

18.

Li D, Shinagawa K, Pang L et al. Effects of angiotensin-converting enzyme inhibition on the development of the atrial fibrillation substrate in dogs with ventricular tachypacinginduced congestive heart failure. Circulation 2001;104:2608-14. 19. Klein HU, Goette A. Blockade of atrial angiotensin II type 1 receptors: a novel antiarrhythmic strategy to prevent atrial fibrillation? J Am Coll Cardiol 2003; 41:2205-06.

19.

Ueng KC , Tsai TP , Yu WC et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J 2003;24:2090-8.

20.

Pedersen OD , Bagger H. , Kober L. , Torp-Pedersen C. Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation 1999;100:376-80.

21.

Vermes E. , Tardif JC , Bourassa MG et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 2003; 107:2926-31.

22.

Olsson LG , Swedberg K. , Ducharme A. et al. CHARM Investigators. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol 2006;47:1997-2004.

23.

Maggioni AP , Latini R. , Carson PE et al. Val-HeFT Investigators. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005;149:548-57.

24.

Moe GK , Allessie MA , Lammers Wjep , Bonke FIM , Hollen J. Experimental evaluation of Moe's multiple wavelet hypothesis of atrial fibrillation . In: Zipes DP and Jalife J (eds.). Cardiac Arrhythmias . San Diego: Grune & Stratton , 1985;265-76.

25.

Dilaveris PE , Gialafos EJ , Chrissos D. et al. Detection of hypertensive patients at risk for paroxysmal atrial fibrillation during sinus rhythm by computer-assisted P wave analysis. J Hypertens 1999;17:1463-70.

26.

Yin YH , Liu ZC , Wu JJ et al. Long-term clinical efficacy of losartan or perindopril combination therapy with low-dose amiodarone in patients with paroxysmal atrial fibrillation . Zhonghua Xin Xue Guan Bing Za Zhi 2006;34:299-302.

27.

Yin Y. , Dalal D. , Liu Z. et al. Prospective randomized study comparing amiodarone vs. amiodarone plus losartan vs. amiodarone plus perindopril for the prevention of atrial fibrillation recurrence in patients with lone paroxysmal atrial fibrillation . Eur Heart J 2006;27:1841-6.

28.

Abuladze GV , Dzhindzholiia NR , Narsiia EV , Dzhincharadze BZ , Kadzhaia TZ The therapeutic efficiency of complex-ACE inhibitor (perindopril) and traditional antiarrhythmic-treatment for prevention atrial fibrillation paroxysms after successful electric cardio version. Georgian Med News 2008;155:17-19.

29.

Fogari R. , Derosa G. , Ferrari I. et al. Effect of valsartan and ramipril on atrial fibrillation recurrence and P-wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation. Am J Hypertens 2008 ;21:1034-9.

30.

Shinagawa K. , Mitamura H. , Ogawa S. , Nattel S. Effects of inhibiting Na(+)/H(+)-exchange or angiotensin converting enzyme on atrial tachycardia-induced remodeling . Cardiovasc Res 2002;54:438-46.

31.

Caballero R. , Delpón E. , Valenzuela C. , Longobardo M. , Tamargo J. Losartan and its metabolite E3174 modify cardiac delayed rectifier K(+) currents. Circulation 2000;101:1199-205.

32.

Li Y. , Li WM , Xue JY , Han W. , Yang SS , Gu HY Effects of losartan on acute atrial electrical remodeling. Chin Med J (Engl) 2004;117:643-6.

33.

Ciulla MM , Paliotti R. , Esposito A. et al. Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial. Circulation 2004;110:552-7.

34.

Ehrlich JR , Hohnloser SH , Nattel S. Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur Heart J 2006;27:512-18.

35.

Wanahita N. , Messerli FH , Bangalore S. , Gami AS , Somers VK , Steinberg JS Atrial fibrillation and obesity - results of a meta-analysis. Am Heart J 2008;155:310-15.

36.

Kosar F. , Aksoy Y. , Ari F. , Keskin L. , Sahin I. P-wave duration and dispersion in obese subjects. Ann Noninvasive Electrocardiol 2008;13:3-7.

37.

Asselbergs FW , van den Berg MP , Bakker SJ et al. N-terminal pro B-type natriuretic peptide levels predict newly detected atrial fibrillation in a population-based cohort . Neth Heart J 2008;16:73-8.